Survodutide (Survodutide (Dual GLP-1/Glucagon Agonist))
A dual agonist of GLP-1 and glucagon receptors being developed for obesity and MASH. Glucagon component provides added metabolic benefits through increased energy expenditure.
How it works
Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism.
Key facts
- Molecular weight: 4,500 Da (approximate)
- Half-life: 5-7 days
- Bioavailability: High (SubQ)
- Storage: Refrigerated 2-8°C.
Dosing overview
- Typical dose: 0.6-6.0 mg
- Frequency: Once weekly
- Duration: Ongoing
- Route: Subcutaneous
Reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Possible side effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Constipation
Research
- Phase 2 survodutide for weight management (2023): Survodutide 4.8mg achieved 18.7% body weight reduction at 46 weeks.
- Survodutide in MASH: Phase 2b results (2024): Up to 83% achieved MASH resolution with significant fibrosis improvement at 48 weeks.
Compare Survodutide
Community discussions about Survodutide
- First week on survodutide 0.6 mg – appetite changes and mild nausea - 4 comments
- My first 8‑week titration with Survodutide – appetite drop and a strange energy dip - 4 comments
- Survodutide Trial: My Week 4 Appetite & Nausea Log - 3 comments
- Survodutide Titration and Appetite Response – Thoughts for a New Compound - 4 comments
- Survodutide First Week: Appetite Drop, Nausea, and HRV Changes - 4 comments
- Ask the community about Survodutide
Research and educational reference only. Not medical advice.